WuXi adds US-based clinical research firm to CRO business

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/NicoElNino)
(Image: Getty/NicoElNino)

Related tags: Wuxi apptec, Wuxi, clinical services, Clinical development, biometrics, preclinical development

WuXi AppTec acquires Pharmapace to bolster its biometrics and clinical development service offerings worldwide.

Following the transaction, financial terms of which were not discosed, Pharmapace will become a wholly-owned subsidiary of WuXi AppTec’s clinical contract research organization (CRO) arm, WuXi Clinical.

Pharmapace, a US-based clinical research services company, provides biometrics services across all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, and medical writing.

Based in San Diego, CA, the addition of Pharmapace enables WuXi Clinical to provide global customers with around-the-clock service.

“This acquisition further enhances WuXi Clinical’s drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost-effectively provide customers seamless biometrics services globally,”​ said Edward Hu, co-CEO of WuXi Apptec in a statement.

In addition to providing full clinical development services, WuXi clinical is a functional service provider (FSP).

Larry Shen, president and CEO of Pharmapace, added, “This combination now allows us to leverage WuXi Apptec’s vast resources to offer customers a truly global solution from preclinical development to clinical development and regulatory submission.”

WuXi AppTec has not responded to a request for comment.

Chinese regulatory reform

After the passing of regulatory reforms​, China can now accept clinical trial data from outside countries, creating opportunities for regional and global collaboration.

Following this change, among other recent reforms, WuXi AppTec acquired US-based ResearchPoint Global​ to expand its clinical research capabilities.

With the acquisition of Pharmapace, WuXi Clinical will have more than 850 employees in China and the US.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us

Products

View more

Webinars